Nova Eye Medical : Investor presentation Half Year Results 31 December 2021

ersonal use only

Nova Eye Medical Limited (ASX:EYE)

Results Presentation for the Six Months Ended 31 December 2021

17 February 2022

Disclaimer

onlyThis presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medical (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This

usepresentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent

ersonalprofessional advice depending upon their specific investment objectives, financial situation or particular needs.

nova-eye.com| 2

only

ASX: Eye Business Snapshot

Nova Eye Medical Limited (ASX:EYE) comprises two business units, Glaucoma and AMD/2RT® -

these segments address the leading causes of blindness in the developed world.

ersonal use

	Nova Eye Medical, Glaucoma
Strategy	Develop, market and sell comprehensive portfolio
of glaucoma consumable surgical devices
FY22 Objectives	Investment in initiatives for sales growth
Market	Glaucoma Surgical Devices; fast-growing and
competitive
Competitive	Proprietary iTrack™ microcatheter technology
Advantage
Sales	Established infrastructure; direct sales in USA,
Germany, Australia; +20 distributors
Manufacturing	California, USA and Dunedin, New Zealand
IP Status	>100 patents issued and pending in major markets
Regulatory	Clearance in all key global markets
Reimbursement	Favorable CPT codes with/without cataract surgery
(USA)

	AlphaRET, AMD
Strategy	Progress 2RT® to market-ready status
FY22 Objectives	Major clinical study; preference to secure
FDA clearance via IDE-approved study
Market	Intermediate Age-related Macular
Degeneration (iAMD) - market not addressed
Competitive	Proprietary 2RT® technology - first mover
Advantage	advantage
Sales	No sales program at present
Manufacturing	Adelaide, Australia
IP Status	>10 patents issued and pending in major
markets
Regulatory	CE Mark (iAMD) in Europe, Australia, NZ and
USA for diabetic eye disease
Reimbursement	Pending

nova-eye.com| 3

Glaucoma Market Strong Global Growth Theme

only		US$610m
	Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness worldwide.
	The aging global population is driving increased glaucoma prevalence and provides strong platform for growth.
			Advancements in diagnostic and imaging technologies
use		CAGR 17%	permit earlier diagnosis, which in turn drives demand
	for interventions which permit earlier treatment
	Glaucoma Surgical
134.2
Device market size
and growth rate	Medications are considered standard of care but are
per annum2
million		compliance, side effects, financial costs
ersonal			associated with significant drawbacks i.e., low patient
people worldwide	US$6.1bn
	with Glaucoma1	Glaucoma surgical device solutions, including devices
		Total Glaucoma	such as iTrack™, are increasingly recognized as a highly
		Treatment Market,	viable alternative to medications - and is currently the
		including pharma,
		fastest growing segment of the ophthalmic market
		market size per
		annum1
1. Market Scope 2021 Glaucoma Surgical Devices Report
2. Market Scope 2021 Glaucoma Surgical Devices Report based on sum of MIGS, Canal Surgery Devices and Glaucoma Tubes and Shunts Markets	nova-eye.com| 4

only

Nova Eye's Market Presence

LEGEND

Population with Glaucoma

Glaucoma Surgical Device Market

ersonal use

5.1 million people1 $455 million

currently growing at 10%1

Nova Eye USA based in Fremont, California with established sales team selling direct to glaucoma surgeons.

5.0 million people1

US$101 million

currently growing at 21%1

Nova Eye Germany based in

Berlin with sales team selling direct to German and Austrian glaucoma surgeons. Third-party distribution partners in the rest of Europe.

11.4 million people1 $23 million

currently growing at 61%1

Well networked Chinese distribution partner with a direct sales force.

1. Marketscope 2021 Glaucoma Surgical Devices Report. Growth in glaucoma surgical devices at the expense of pharmaceuticals.

nova-eye.com| 5